Radiopharm Theranostics RADX
NASDAQ RADX
$1.48 -0.14 (-8.64%)
At close: Oct 1, 2026 · 4:00 PM EDT

Radiopharm Theranostics (RADX) Liabilities and Shareholders Equity (2024 - 2026)

Updated

Radiopharm Theranostics (RADX) posted Liabilities and Shareholders Equity of $426,560 for fiscal Q4 2026 (quarter ended Jun 30, 2026), down 23.0% from $553,859 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics' Liabilities and Shareholders Equity came in at $408,403, down 99.5% from FY2025.

  • In prior fiscal years, Radiopharm Theranostics' Liabilities and Shareholders Equity was $86.48 million in FY2025 and $474,737 in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Radiopharm Theranostics 5.74 Bn 5.70 Bn 186,835.86 426,559.54
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 426,559.54
Jun 30, 2025 553,858.65
Dec 31, 2024 92.45 Mn
Jun 30, 2024 474,737.15
API Access

Radiopharm Theranostics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=RADX&period=max&api_key=YOUR_API_KEY